At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Vicks Cough Syrup for Chesty Coughs +2 moredrug
Likely dose
Vicks Cough Syrup for Chesty Coughs 15 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open- Label, Randomized, Multiple-dose, 3-way Crossover Relative Bioavailability Study to Characterize the Pharmacokinetics of the 3 Marketed Products Containing 200 mg Guaifenesin Under Fasted Conditions in Normal Healthy Subjects.
In Brief
A Phase 1 clinical trial evaluating Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Strength Chest Congestion, and 1 other intervention for Healthy Subjects. Completed, enrolled 30 participants.
Detailed Summary
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
Primary CompletionJul 2009
First PostedAug 2018
TodayJul 2026
First PostedAug 23, 2018
Enrollment StartJun 30, 2009
Primary CompletionJul 16, 2009
TodayJul 2, 2026
Enrollment to primary: 16 daysPosted 7.9 years ago
Interventions
Vicks Cough Syrup for Chesty Coughsdrug
Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Robitussin Extra Strength Chest Congestiondrug
Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Organ-I- NR tabletdrug
Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water